Table Info

Table 2.

The characteristics of articles included in a systematic review of the effect of COVID-19 on HCC treatment

Reference	Place (country)	Sample size	Type of study	Review period or comparison date	Quality assessment
Aghemo et al. [28]	Italy	194 Italian AISF members	Prospective web-based survey	From April 8, 2020 to May 3, 2020	Fair
Buonaguro et al. [34]	Naples and Italy	NA	NA	March 2020 compared to 2019	Poor
El Kassas et al. [42]	Egypt	NA	NA	Letter without data	Poor
Kounis et al. [35]	France	32 Patients with HCC	NA	Between April 15 and May 15, 2020 vs. the same time in 2019	Poor
Iavarone et al. [29]	Italy	2019: 117 2020: 77	NA	From February to March 20, 2020 vs. the same time in 2019	Poor
Mario et al. [39]	Italy	2019: 12 2020: 7	Single-center study	March 9 to April 30, 2019 vs. the same time in 2020	Fair
Martinez et al. [30]	Latin American	229 Centres	Global survey	From May 6 to May 30, 2020	Fair
Toyoda et al. [31]	US, Japan, and Singapore	3 Medical centers	Survey	March 1 to March 14, 2018, 2019, and 2020 and March 15 to May 1, 2018, 2019, and 2020	Fair
Amaddeo et al. [19]	France	6 Referral centers (670): 2020: 293 2019: 377	Retrospectiveand cross-sectional study	First 6 weeks of the COVID-19 pandemic (exposed) vs. the same period in 2019 (non-exposed)	Good
Bargellini et al. [40]	Italy	2019: 487 2020: 353	Retrospective	From the lockdown started until the phase of exiting the lockdown vs. the same time in 2019	Good
Crespo et al. [32]	Spain	81 Hospitals	Multicenter nationwide survey	Between March 30 and April 3, 2020	Good
Gandhi et al. [18]	14 Asia-Pacific countries	2,789 vs. 2,045 patients with new HCC diagnoses	Survey	February to May 2019 (pre-pandemic) vs. the same period in 2020 (pandemic period)	Good
Hartl et al. [38]	Austria	279 Cohort 1 and 138 cohort 2	Telesurvey	December 2019 to February 2020 and March to May 2020	Good
Jin et al. [41]	China	2020: 71, study group 2019: 83, control group	Retrospective	From January 2020 to March 2020 compared with the same period in 2019	Good
Iavarone et al. [25]	Italy	2019: 555 2020: 579	Retrospective study	2020 vs. 2019	Good
Muñoz-Martínez et al. [26]	76 Countries	76 Centers around the world	International survey	From May 2020 to June 2020	Fair
Pomej et al. [22]	Austria	104 Males 22 Females	Retrospectively	Between December 30, 2019 and June 30, 2020	Good
Ponziani et al. [37]	Italy	55 Different units present in 43 Italian hospitals	Online survey	January 15 to March 15, 2021 (second/third pandemic waves) vs. the same time in 2020	Good
Tan et al. [36]	Hong Kong (China) and Singapore	111	Modelling study	June 1, 2019 to May 30, 2020	Good
Zhao et al. [33]	China	42 Class-A tertiary hospital, 664 doctors	Nationwide online questionnaire survey	In COVID-19 period	Good

AISF: Association for the Study of the Liver

Declarations

Author contributions

HS and AM: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. SSB: Writing—original draft, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, et al. Impact of the COVID-19 pandemic on cancer care: a global vollaborative study. JCO Glob Oncol. 2020;6:1428–38. [DOI] [PubMed] [PMC]

Amador M, Matias-Guiu X, Sancho-Pardo G, Contreras Martinez J, de la Torre-Montero JC, Peñuelas Saiz A, et al. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open. 2021;6:100157. [DOI] [PubMed] [PMC]

Allahqoli L, Mazidimoradi A, Momenimovahed Z, Rahmani A, Hakimi S, Tiznobaik A, et al. The global incidence, mortality, and burden of breast cancer in 2019: correlation with smoking, drinking, and drug use. Front Oncol. 2022;12:921015. [DOI] [PubMed] [PMC]

Hesary FB, Salehiniya H. The impact of the COVID-19 epidemic on diagnosis, treatment, concerns, problems, and mental health in patients with gastric cancer. J Gastrointest Cancer. 2022;53:797–804. [DOI] [PubMed] [PMC]

Gralnek IM, Hassan C, Dinis-Ribeiro M. COVID-19 and endoscopy: implications for healthcare and digestive cancer screening. Nat Rev Gastroenterol Hepatol. 2020;17:444–6. [DOI] [PubMed] [PMC]

Momenimovahed Z, Salehiniya H, Hadavandsiri F, Allahqoli L, Günther V, Alkatout I. Psychological distress among cancer patients during COVID-19 pandemic in the world: a systematic review. Front Psychol. 2021;12:682154. [DOI] [PubMed] [PMC]

Momenimovahed Z, Salehiniya H. Delay in the diagnosis of breast cancer during coronavirus pandemic. EXCLI J. 2021;20:142–4. [DOI] [PubMed] [PMC]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Mohammadian M, Soroush A, Mohammadian-Hafshejani A, Towhidi F, Hadadian F, Salehiniya H. The incidence and mortality of liver cancer and their relationship with development in Asia. Asian Pac J Cancer Prev. 2016;17:2041–7. [DOI] [PubMed]

10.

Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, et al. “Complimenting the complement”: mechanistic insights and opportunities for therapeutics in hepatocellular carcinoma. Front Oncol. 2021;10:627701. [DOI] [PubMed] [PMC]

11.

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;109:djx030. [DOI] [PubMed] [PMC]

12.

Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, et al. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J. 2020;19:108–30. [DOI] [PubMed] [PMC]

13.

Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis. Hepatology. 2020;72:1654–65. [DOI] [PubMed] [PMC]

14.

Mani I, Alexopoulou A. Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic. Ann Gastroenterol. 2021;34:1–9. [DOI] [PubMed] [PMC]

15.

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa: Ottawa Hospital Research Institute; c2021 [cited 2022 Oct 12]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

16.

De Vincentiis L, Carr RA, Mariani MP, Ferrara G. Cancer diagnostic rates during the 2020 ‘lockdown’, due to COVID-19 pandemic, compared with the 2018–2019: an audit study from cellular pathology. J Clin Pathol. 2021;74:187–9. [DOI] [PubMed]

17.

Ferrara G, De Vincentiis L, Ambrosini-Spaltro A, Barbareschi M, Bertolini V, Contato E, et al. Cancer diagnostic delay in northern and central Italy during the 2020 lockdown due to the coronavirus disease 2019 pandemic: assessment of the magnitude of the problem and proposals for corrective actions. Am J Clin Pathol. 2021;155:64–8. [DOI] [PubMed] [PMC]

18.

Gandhi M, Ling WH, Chen CH, Lee JH, Kudo M, Chanwat R, et al. Impact of COVID-19 on hepatocellular carcinoma management: a multicountry and region study. J Hepatocell Carcinoma. 2021;8:1159–67. [DOI] [PubMed] [PMC]

19.

Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, et al.; Paris Liver Cancer Group. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. JHEP Rep. 2021;3:100199. [DOI] [PubMed] [PMC]

20.

Kempf E, Lamé G, Layese R, Priou S, Chatellier G, Chaieb H, et al.; Assistance Publique – Hôpitaux de Paris Cancer Group. New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: a persistent and concerning decrease long after the end of the national lockdown. Eur J Cancer. 2021;150:260–7. [DOI] [PubMed] [PMC]

21.

Khan A, Bilal M, Morrow V, Cooper G, Thakkar S, Singh S. Impact of the coronavirus disease 2019 pandemic on gastrointestinal procedures and cancers in the United States: a multicenter research network study. Gastroenterology. 2021;160:2602–4.e5. [DOI] [PubMed] [PMC]

22.

Pomej K, Scheiner B, Hartl L, Balcar L, Meischl T, Mandorfer M, et al. COVID-19 pandemic: impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. PLoS One. 2021;16:e0256544. [DOI] [PubMed] [PMC]

23.

Vigliar E, Cepurnaite R, Alcaraz-Mateos E, Ali SZ, Baloch ZW, Bellevicine C, et al. Global impact of the COVID-19 pandemic on cytopathology practice: results from an international survey of laboratories in 23 countries. Cancer Cytopathol. 2020;128:885–94. [DOI] [PubMed]

24.

Grinspan LT, Rustgi SD, Itzkowitz SH, Polydorides AD, Lucas AL. Impact of COVID-19 pandemic on gastrointestinal cancer diagnosis and resection: an observational study. Clin Res Hepatol Gastroenterol. 2022;46:101839. [DOI] [PubMed] [PMC]

25.

Iavarone M, Antonelli B, Ierardi AM, Topa M, Sangiovanni A, Gori A, et al. Reshape and secure HCC managing during COVID-19 pandemic: a single centre analysis of four periods in 2020 versus 2019. Liver Int. 2021;41:3028–32. [DOI] [PubMed] [PMC]

26.

Muñoz-Martínez S, Sapena V, Forner A, Nault JC, Sapisochin G, Rimassa L, et al. Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Rep. 2021;3:100260. [DOI] [PubMed] [PMC]

27.

Perisetti A, Kaur R, Thandassery R. Increased diagnosis of hepatocellular carcinoma in hospitalized patients with alcohol related hepatitis after the Covid-19 outbreak: a global multi-center propensity matched analysis. Clin Gastroenterol Hepatol. 2021;19:2450–1.e1. [DOI] [PubMed] [PMC]

28.

Aghemo A, Masarone M, Montagnese S, Petta S, Ponziani FR, Russo FP; Associazione Italiana Studio Fegato (AISF). Assessing the impact of COVID-19 on the management of patients with liver diseases: a national survey by the Italian association for the study of the liver. Dig Liver Dis. 2020;52:937–41. [DOI] [PubMed] [PMC]

29.

Iavarone M, Sangiovanni A, Carrafiello G, Rossi G, Lampertico P. Management of hepatocellular carcinoma in the time of COVID-19. Ann Oncol. 2020;31:1084–5. [DOI] [PubMed] [PMC]

30.

Martinez D, Sarria GJ, Wakefield D, Flores C, Malhotra S, Li B, et al. COVID’s impact on radiation oncology: a Latin American survey study. Int J Radiat Oncol Biol Phys. 2020;108:374–8. [DOI] [PubMed] [PMC]

31.

Toyoda H, Huang DQ, Le MH, Nguyen MH. Liver care and surveillance: the global impact of the COVID-19 pandemic. Hepatol Commun. 2020;4:1751–7. [DOI] [PubMed] [PMC]

32.

Crespo J, Fernández Carrillo C, Iruzubieta P, Hernández-Conde M, Rasines L, Jorquera F, et al.; COVID-19 SEPD/AEEH Group. Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. J Gastroenterol Hepatol. 2021;36:1627–33. [DOI] [PubMed]

33.

Zhao H, Zhou A, Zhou J, Bi X, Yan S, Jin J, et al. Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey. HPB (Oxford). 2022;24:342–52. [DOI] [PubMed] [PMC]

34.

Buonaguro FM, Botti G, Ascierto PA, Pignata S, Ionna F, Delrio P, et al.; INT-Pascale COVID-19 Crisis Unit. The clinical and translational research activities at the INT - IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic. Infect Agent Cancer. 2020;15:69. [DOI] [PubMed] [PMC]

35.

Kounis I, Duhaut L, Breard T, Samuel D, Coilly A. Impact of COVID - 19 in patients awaiting liver transplantation. Liver Int. 2022;42:256–7. [DOI] [PubMed] [PMC]

36.

Tan EXX, Quek WL, Suryadi, Chahed H, Iyer SG, Jeyaraj PR, et al. Impact of COVID-19 on liver transplantation in Hong Kong and Singapore: a modelling study. Lancet Reg Health West Pac. 2021;16:100262. [DOI] [PubMed] [PMC]

37.

Ponziani FR, Aghemo A, Cabibbo G, Masarone M, Montagnese S, Petta S, et al.; AISF COVID-19 survey group. Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: a web-based survey. Liver Int. 2021;41:2228–32. [DOI] [PubMed]

38.

Hartl L, Semmler G, Hofer BS, Schirwani N, Jachs M, Simbrunner B, et al. COVID-19-related downscaling of in-hospital liver care decreased patient satisfaction and increased liver-related mortality. Hepatol Commun. 2021;5:1660–75. [DOI] [PubMed] [PMC]

39.

Mario G, Federico C, Matteo R, Elena B, Paolo DR. COVID-19 and elective general surgery. Acta Biomed. 2020;91:e2020152.

40.

Bargellini I, Boni G, Traino AC, Bozzi E, Lorenzoni G, Bianchi F, et al. Management of liver tumors during the COVID-19 pandemic: the added value of selective internal radiation therapy (SIRT). J Clin Med. 2021;10:4315. [DOI] [PubMed] [PMC]

41.

Jin ZC, Chen L, Zhong BY, Zhu HD, Zeng CH, Li R, et al. Impact of COVID-19 pandemic on intervals and outcomes of repeated transarterial chemoembolization in patients with hepatocellular carcinoma. Front Oncol. 2021;11:602700. [DOI] [PubMed] [PMC]

42.

El Kassas M, Abdelkader H, Medhat MA. COVID-19 in Egypt: through crisis to adaptation; a gastroenterologist's perspective. Arab J Gastroenterol. 2020;21:207–10. [DOI] [PubMed] [PMC]

43.

Chen JG, Zhang YH, Lu LL, Chen HZ, Shen AG, Zhu YR. Liver cancer screening in China: practices and its extended questions. Hepatoma Res. 2019;5:12. [DOI]

44.

Amit S, Jorge AM. Screening for hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2008;4:201–8. [PubMed] [PMC]

45.

Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B, et al. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut. 2021;70:401–7. [DOI] [PubMed] [PMC]

46.

Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7:308–19. [DOI] [PubMed] [PMC]

47.

McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4–13. [DOI] [PubMed] [PMC]

48.

Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A practical guideline for hepatocellular carcinoma screening in patients at risk. Mayo Clin Proc Innov Qual Outcomes. 2019;3:302–10. [DOI] [PubMed] [PMC]

49.

Marquardt P, Liu PH, Immergluck J, Olivares J, Arroyo A, Rich NE, et al. Hepatocellular carcinoma screening process failures in patients with cirrhosis. Hepatol Commun. 2021;5:1481–9. [DOI] [PubMed] [PMC]

50.

Kuo MJ, Mo LR, Chen CL. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer. 2021;21:250. [DOI] [PubMed] [PMC]

51.

Kamble S, Joshi A, Kamble R, Kumari S. Influence of COVID-19 pandemic on psychological status: an elaborate review. Cureus. 2022;14:e29820. [DOI] [PubMed] [PMC]

52.

Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, et al. Treatment strategies for hepatocellular carcinoma—a multidisciplinary approach. Int J Mol Sci. 2019;20:1465. [DOI] [PubMed] [PMC]

53.

Cassese G, Han HS, Lee B, Lee HW, Cho JY, Troisi RI. The role of minimally invasive surgery in the treatment of HCC. Hepatoma Res. 2022;8:26. [DOI]

54.

Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–7. [DOI] [PubMed]

55.

Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285–92. [DOI] [PubMed]

56.

Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624. [DOI] [PubMed] [PMC]

57.

Alkatout I, Biebl M, Momenimovahed Z, Giovannucci E, Hadavandsiri F, Salehiniya H, et al. Has COVID-19 affected cancer screening programs? A systematic review. Front Oncol. 2021;11:675038. [DOI] [PubMed] [PMC]